Overexpression of Her2/neu is implicated in the development of resistance to the
antiestrogen tamoxifen (TAM) that exerts its inhibitory effect through interaction with estrogen …

Abstract HER2/neu (erb B-2) overexpression has been causally associated with tamoxifen
resistance in human breast cancer cells. Forced expression of HER2 in MCF-7 breast …

Background: Patients receiving adjuvant tamoxifen whose tumors express high levels of
both HER2/neu (HER2) and the estrogen receptor (ER) coactivator AIB1 often develop …

Purpose To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in
paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at …

Tamoxifen has been used for the systemic treatment of patients with breast cancer for nearly
three decades. Treatment success is primarily dependent on the presence of the estrogen …

Resistance to tamoxifen is a major clinical challenge in the treatment of breast cancer;
however, it is still unclear which signaling pathways are the major drivers of tamoxifen …

Currently, the standard of care for estrogen receptor (ER)-positive breast cancer is 5 years of
tamoxifen (TAM) or an aromatase inhibitor (AI) such as anastrozole. New studies indicate …

Introduction The inhibition of estrogen receptor (ER) α action with the ER antagonist
tamoxifen is an established treatment in the majority of breast cancers. De novo or acquired …

Estrogen receptors (ER) are expressed in∼ 65% of human breast cancer. Cumulative data
from clinical trials and retrospective analyses suggest that some chemotherapeutic agents …

Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or
acquired tumor resistance. Recent clinical evidence indicates that loss of expression of …